carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['duo-o', 'ovarian']
insightful report of results from the randomized, placebo (pbo)-controlled phase iii duo-o trial from philipp harter at #asco23. read more immunotherapy research for ovarian cancer in #jitc with this article from lingfang xia et al 
The official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. #JITC Interim Editor-in-Chief: James L. Gulley (@gulley1)